Study guide

7.2 Heart Failure, Cardiomyopathies & Valvular Disease

USMLE Step 2 CK Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Human Development & Well-Patient Care

1.1 Infant, Child & Adolescent Development & Growth 1.2 Adult Development, Aging & Geriatric Assessment 1.3 Preventive Health, Immunization & Well-Patient Screening

2 Chapter 2: Immune System & Immunologic Disorders

2.1 Primary & Secondary Immunodeficiencies 2.2 Hypersensitivity Reactions, Allergy & Anaphylaxis 2.3 Autoimmune & Rheumatologic Disease Principles

3 Chapter 3: Blood & Lymphoreticular System

3.1 Anemias: Microcytic, Normocytic & Macrocytic Etiologies 3.2 Bleeding Disorders, Coagulopathies & Platelet Pathology 3.3 Hematologic Malignancies & Lymphoproliferative Disorders

4 Chapter 4: Behavioral Health & Psychiatric Disorders

4.1 Mood Disorders: Major Depression & Bipolar Spectrum 4.2 Anxiety, Trauma-Related & Somatic Symptom Disorders 4.3 Psychotic Disorders & Schizophrenia Spectrum 4.4 Substance Use Disorders & Psychopharmacology

5 Chapter 5: Nervous System & Special Senses

5.1 Cerebrovascular Disease, Stroke & Transients 5.2 Seizures, Epilepsy & Altered Mental Status 5.3 Movement Disorders, Dementia & Peripheral Neuropathies 5.4 Special Senses: Ophthalmologic & Otolaryngologic Emergencies

6 Chapter 6: Musculoskeletal System & Dermatology

6.1 Fractures, Dislocations & Orthopedic Trauma 6.2 Inflammatory Arthropathies & Crystal-Induced Diseases 6.3 Inflammatory & Infectious Dermatoses 6.4 Cutaneous Malignancies & Blistering Disorders

7 Chapter 7: Cardiovascular System

7.1 Coronary Artery Disease & Acute Coronary Syndromes 7.2 Heart Failure, Cardiomyopathies & Valvular Disease 7.3 Cardiac Arrhythmias, Conduction Blocks & EKG Interpretation 7.4 Vascular Emergencies: Aortic Aneurysms & Peripheral Arterial Disease

8 Chapter 8: Respiratory System

8.1 Obstructive Airway Diseases: Asthma & COPD 8.2 Infectious Pneumonias & Pleural Effusions 8.3 Pulmonary Vascular Disease & Thromboembolism 8.4 Acute Respiratory Distress Syndrome & Interstitial Lung Diseases

9 Chapter 9: Gastrointestinal System

9.1 Esophageal, Gastric & Peptic Ulcer Disorders 9.2 Inflammatory Bowel Disease & Colorectal Neoplasms 9.3 Hepatic Disorders, Cirrhosis & Portal Hypertension 9.4 Biliary Tract Diseases & Pancreatitis

10 Chapter 10: Renal, Urinary & Reproductive Systems

10.1 Acute Kidney Injury & Chronic Kidney Disease 10.2 Glomerular & Tubulointerstitial Diseases 10.3 Nephrolithiasis, Urinary Tract Infections & Prostate Pathology 10.4 Fluid, Electrolyte & Acid-Base Disorders 10.5 Female Reproductive Disorders & Gynecology 10.6 Breast Pathology & Clinical Breast Disease

11 Chapter 11: Pregnancy, Childbirth & Puerperium

11.1 Normal Prenatal Care & Maternal-Fetal Physiology 11.2 Medical & Obstetric Complications of Pregnancy 11.3 Labor, Delivery & Postpartum Management

12 Chapter 12: Endocrine System

12.1 Diabetes Mellitus, Hypoglycemia & Metabolic Emergencies 12.2 Thyroid & Parathyroid Disorders 12.3 Adrenal & Pituitary Axis Pathology

13 Chapter 13: Multisystem Processes & Critical Care

13.1 Shock States, Sepsis & Systemic Inflammatory Response 13.2 Environmental Emergencies, Toxicology & Overdose 13.3 Infectious Disease Principles & Systemic Pathogens

14 Chapter 14: Biostatistics, Epidemiology & Literature Interpretation

14.1 Study Designs, Bias & Validity 14.2 Diagnostic Testing: Sensitivity, Specificity, PPV & NPV 14.3 Statistical Significance, Risk Measures & Evidence-Based Medicine

15 Chapter 15: Social Sciences, Ethics & Systems-Based Practice

15.1 Medical Ethics, Informed Consent & Patient Autonomy 15.2 Legal Issues, Confidentiality & Surrogate Decision Making 15.3 Patient Safety, Quality Improvement & Medical Error Analysis 15.4 Health Care Delivery Systems, Interprofessional Care & Transitions

7.2 Heart Failure, Cardiomyopathies & Valvular Disease

Key Takeaways Explain This Topic AI

Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF, LVEF <=40%) requires four foundational drug classes that reduce mortality: ARNI (sacubitril/valsartan), evidence-based beta-blockers (carvedilol, metoprolol succinate, bisoprolol), mineralocorticoid receptor antagonists (spironolactone or eplerenone), and SGLT2 inhibitors (dapagliflozin or empagliflozin).

When transitioning a patient from an ACE inhibitor to sacubitril/valsartan (ARNI), a mandatory 36-hour washout period must be observed to prevent severe angioedema caused by dual inhibition of neprilysin and ACE.

Hypertrophic cardiomyopathy (HCM) features asymmetric septal hypertrophy causing dynamic left ventricular outflow tract (LVOT) obstruction; the characteristic systolic ejection murmur increases with maneuvers that decrease LV preload or afterload (Valsalva, standing) and decreases with maneuvers that increase LV volume or afterload (squatting, handgrip, passive leg raise).

Primary implantable cardioverter-defibrillator (ICD) placement is indicated for primary prevention of sudden cardiac death in patients with HFrEF (LVEF <=35%) who remain symptomatic (NYHA Class II-III) despite at least 3 months of optimal GDMT.

Aortic stenosis intervention (surgical aortic valve replacement [SAVR] or transcatheter aortic valve replacement [TAVR]) is indicated for any patient with symptomatic severe aortic stenosis (valve area <1.0 cm2, mean gradient >40 mmHg, or peak velocity >4.0 m/s), or asymptomatic patients with LVEF <50%.

Last updated: July 2026

Heart Failure, Cardiomyopathies & Valvular Disease

Heart failure (HF) and valvular heart diseases require a comprehensive understanding of myocardial mechanics, neurohormonal pathways, physical examination findings, and guideline-directed interventions. On USMLE Step 2 CK, questions emphasize pharmacologic mortality benefits, hemodynamic profiling of acute decompensation, cardiomyopathy differentiation, and indications for valve repair or replacement.

Heart Failure Classification & Clinical Diagnosis

Heart failure is defined by the inability of the heart to pump sufficient blood to meet metabolic demands or doing so only at elevated filling pressures.

Phenotypic Classification

Heart Failure with Reduced Ejection Fraction (HFrEF): Left ventricular ejection fraction (LVEF) ≤ 40 % \le 40\% ≤ 40% . Primary defect is impaired systolic contraction (inotropic failure).

Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF): LVEF 41 – 49 % 41\text{--}49\% 41 – 49% .

Heart Failure with Preserved Ejection Fraction (HFpEF): LVEF ≥ 50 % \ge 50\% ≥ 50% . Primary defect is impaired diastolic relaxation and compliance (lusitropic failure), frequently secondary to chronic hypertension, aging, obesity, or amyloidosis.

Diagnostic Biomarkers & Physical Exam

B-type Natriuretic Peptide (BNP > 100 pg/mL >100\text{ pg/mL} > 100 pg/mL ) & NT-proBNP ( > 300 pg/mL >300\text{ pg/mL} > 300 pg/mL ): Released by ventricular myocytes in response to wall stretch. Excellent negative predictive value to rule out heart failure in acute dyspnea.

Physical Exam Findings: S3 gallop (pathognomonic for LV volume overload in HFrEF), elevated jugular venous pressure (JVP > 8 cm H 2 O >8\text{ cm H}_2\text{O} > 8 cm H 2 ​ O ), hepatojugular reflux, bilateral basilar crackles, and peripheral pitting edema. An S4 gallop indicates atrial contraction into a stiffened LV (characteristic of HFpEF and LVH).

Guideline-Directed Medical Therapy (GDMT) for HFrEF

Modern management of HFrEF (LVEF ≤ 40 % \le 40\% ≤ 40% ) centers on four foundational pillars of GDMT that independently reduce overall mortality, heart failure hospitalizations, and sudden cardiac death:

GDMT Pillar Drug Class Specific Agents & Dosages Clinical Pearls & Mandatory Precautions

1. Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Sacubitril / Valsartan Preferred over ACEi/ARB. Mandatory 36-hour washout period required when switching from an ACE inhibitor to prevent severe angioedema .

2. Evidence-Based Beta-Blockers Carvedilol , Metoprolol Succinate , Bisoprolol Reduces mortality by decreasing sympathetic drive. Do not initiate during acute decompensation ; introduce only when euvolemic.

3. Mineralocorticoid Receptor Antagonists (MRA) Spironolactone , Eplerenone Reduces aldosterone-mediated myocardial fibrosis. Monitor serum potassium ( K + < 5.0 mEq/L \text{K}^+ <5.0\text{ mEq/L} K + < 5.0 mEq/L ) and renal function ( CrCl > 30 mL/min \text{CrCl} >30\text{ mL/min} CrCl > 30 mL/min ).

4. SGLT2 Inhibitors Dapagliflozin , Empagliflozin Reduces heart failure hospitalizations and cardiovascular death regardless of whether the patient has type 2 diabetes.

Additional Pharmacologic & Device Therapies

Hydralazine plus Isosorbide Dinitrate: Mortality benefit in self-identified Black patients with NYHA Class III–IV HFrEF despite optimal GDMT, or patients intolerant to ARNI/ACEi/ARB due to renal failure or hyperkalemia.

Loop Diuretics (Furosemide, Bumetanide): Essential for symptom relief of volume overload. Does NOT confer a mortality benefit.

Ivabradine: Selective I f I_f I f ​ current inhibitor in the SA node. Indicated in patients with symptomatic HFrEF (LVEF ≤ 35 % \le 35\% ≤ 35% ), in sinus rhythm with a resting heart rate ≥ 70 bpm \ge 70\text{ bpm} ≥ 70 bpm despite maximum tolerated beta-blocker therapy.

Implantable Cardioverter-Defibrillator (ICD): Primary prevention of sudden cardiac death in HFrEF with LVEF ≤ 35 % \le 35\% ≤ 35% and NYHA Class II–III symptoms after ≥ 3 months \ge 3\text{ months} ≥ 3 months of optimal GDMT, or post-MI LVEF ≤ 35 % \le 35\% ≤ 35% after ≥ 40 days \ge 40\text{ days} ≥ 40 days .

Cardiac Resynchronization Therapy (CRT): Biventricular pacing indicated for LVEF ≤ 35 % \le 35\% ≤ 35% , sinus rhythm, LBBB morphology, and QRS duration ≥ 150 ms \ge 150\text{ ms} ≥ 150 ms .

Cardiomyopathies: Clinical Spectrum & Differentiation

Feature Dilated Cardiomyopathy (DCM) Hypertrophic Cardiomyopathy (HCM) Restrictive Cardiomyopathy (RCM)

Pathophysiology Ventricular dilation, systolic dysfunction (LVEF < 40 % <40\% < 40% ). Asymmetric septal hypertrophy, dynamic LVOT obstruction, diastolic dysfunction. Rigid myocardium, severe diastolic dysfunction, preserved LVEF ( > 50 % >50\% > 50% ).

Etiologies Idiopathic, viral myocarditis (Coxsackie B), alcohol abuse, doxorubicin, peripartum, ischemia. Autosomal dominant mutations in sarcomeric proteins ( MYH7 , MYBPC3 ). Cardiac amyloidosis , sarcoidosis, hemochromatosis, radiation, scleroderma.

Physical Exam & EKG S3 gallop , cardiomegaly, displaced PMI. Harsh systolic ejection murmur at LLSB. S4 gallop . Kussmaul sign (JVP rises on inspiration). EKG: Low voltage despite thick LV walls (amyloid).

Treatment Notes Standard GDMT for HFrEF. Abstinence from alcohol. Beta-blockers or verapamil (first-line). Avoid diuretics, nitrates, and inotropes. Treat underlying etiology. Diuretics for volume overload. Heart transplant.

Diagnostic Maneuvers in Hypertrophic Cardiomyopathy

In HCM with dynamic LVOT obstruction, systolic anterior motion (SAM) of the anterior mitral valve leaflet contacts the hypertrophied septum during systole.

Maneuvers that DECREASE LV Preload/Volume (Valsalva strain phase, sudden standing, nitroglycerin): INCREASE murmur intensity (smaller LV chamber size worsens obstruction).

Maneuvers that INCREASE LV Preload/Afterload (Squatting, passive leg raise, sustained handgrip): DECREASE murmur intensity (larger LV chamber separates septum from mitral valve).

  • Valvular Heart Diseases & Surgical Indications
  • Valvular Lesion Diagnostic Summary

Valvular Lesion Physical Exam & Murmur Characteristics Classic Clinical Scenario & Complications

Aortic Stenosis (AS) Crescendo-decrescendo systolic murmur at 2nd RICS radiating to carotids. Pulsus parvus et tardus (weak, delayed carotid pulse). Soft/absent S2. SAD triad: Syncope, Angina, Dyspnea. Caused by age-related calcification or bicuspid aortic valve.

Aortic Regurgitation (AR) Early diastolic decrescendo murmur at 3rd LICS. Bounding pulses ( Water-hammer pulse ), wide pulse pressure, Austin Flint murmur . Endocarditis, aortic dissection, Marfan syndrome. LV volume overload leading to eccentric hypertrophy.

Mitral Stenosis (MS) Opening snap followed by mid-diastolic rumbling murmur with presystolic accentuation at apex (left lateral decubitus position). History of Rheumatic Fever (Group A Strep). Causes atrial fibrillation, LA enlargement, and Ortner syndrome (hoarseness from recurrent laryngeal nerve compression).

Mitral Regurgitation (MR) Holosystolic murmur at apex radiating to axilla. Prominent S3 gallop. Ischemic papillary muscle rupture, MVP, endocarditis. Acute MR causes sudden pulmonary edema.

Mitral Valve Prolapse (MVP) Mid-systolic click followed by late systolic murmur at apex. Young females, connective tissue disorders. Squatting delays click/murmur; standing moves click earlier.

Surgical Criteria for Valvular Interventions

Severe Aortic Stenosis Criteria: Valve area < 1.0 cm 2 <1.0\text{ cm}^2 < 1.0 cm 2 , mean pressure gradient > 40 mmHg >40\text{ mmHg} > 40 mmHg , or peak velocity > 4.0 m/s >4.0\text{ m/s} > 4.0 m/s .

Indications for AVR (SAVR or TAVR): Presence of any symptoms (syncope, angina, dyspnea), OR asymptomatic with LVEF < 50 % <50\% < 50% , OR undergoing concurrent cardiac surgery.

Mitral Regurgitation: Surgical repair or replacement indicated for symptomatic severe MR, or asymptomatic severe MR with LVEF 30–60% or LV end-systolic diameter (LVESD) ≥ 40 mm \ge 40\text{ mm} ≥ 40 mm .

Mitral Stenosis: Percutaneous mitral balloon commissurotomy (PMBC) indicated for symptomatic moderate-to-severe MS with favorable valve morphology and absence of LA thrombus.